Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 1;4(1):e000135.
doi: 10.1136/ihj-2022-000135. eCollection 2022.

Evolving role of novel COVID-19 Medicine Delivery Units

Alice Packham #  1 , Niamh Spence #  1 , Anna Goodman  1   2   3
Affiliations

Evolving role of novel COVID-19 Medicine Delivery Units

Alice Packham et al. Integr Healthc J. .
No abstract available

Keywords: COVID-19; evidence-based practice; health policy; health services research; prehospital care.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AG—principal investigator for the PANORAMIC, COV002, COV009, NOVAVAX, COMCOV2, COVBOOST and TICO trials at St Thomas’ Hospital, London. NS and AP—co-investigators for the PANORAMIC, COV002, COV009, NOVAVAX, COMCOV2, COVBOOST, ENSEMBLE-2, AZ-BOOST, RECOVERY, HEAL-COVID, SPRINTER, GILEAD and TICO trials at St Thomas’ Hospital, London.

Figures

Figure 1
Figure 1
Referral pathway for COVID 19 Medicine Delivery Unit (CMDU).
See this image and copyright information in PMC

References

    1. Interim clinical commissioning policy: antivirals or neutralising monoclonal antibodies for non-hospitalised patients with COVID-19 (version 5). England N; 2022. https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/...
    1. Salama C, Han J, Yau L, et al. . Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021;384:20–30. 10.1056/NEJMoa2030340 - DOI - PMC - PubMed
    1. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. . Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab. N Engl J Med 2021;385:1941–50. 10.1056/NEJMoa2107934 - DOI - PubMed
    1. MHpR A . Summary of Product Characteristics for Xevudy: Medicines & Healthcare products Regulatory Agency; 2021. Available: https://www.gov.uk/government/publications/regulatory-approval-of-xevudy...
    1. Hammond J, Leister-Tebbe H, Gardner A, et al. . Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med Overseas Ed 2022;386:1397–408. 10.1056/NEJMoa2118542 - DOI - PMC - PubMed

LinkOut - more resources